Fig. 3From: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world studyPatient satisfaction with aspects of Ig20Gly administration (assessed using the Treatment Preference Questionnaire). n = 101 patients. a n = 100 patients. Ig20Gly, Immune Globulin Subcutaneous (Human) 20% solutionBack to article page